Breast Cancer Research and Treatment

, Volume 119, Issue 3, pp 551–558

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

  • Marieke E. Straver
  • Annuska M. Glas
  • Juliane Hannemann
  • Jelle Wesseling
  • Marc J. van de Vijver
  • Emiel J. Th. Rutgers
  • Marie-Jeanne T. F. D. Vrancken Peeters
  • Harm van Tinteren
  • Laura J. van‘t Veer
  • Sjoerd Rodenhuis
Preclinical Study

DOI: 10.1007/s10549-009-0333-1

Cite this article as:
Straver, M.E., Glas, A.M., Hannemann, J. et al. Breast Cancer Res Treat (2010) 119: 551. doi:10.1007/s10549-009-0333-1

Abstract

The 70-gene signature (MammaPrint™) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II–III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.

Keywords

Breast cancerNeoadjuvantChemosensitivityPredictiveGene expression signature

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Marieke E. Straver
    • 1
  • Annuska M. Glas
    • 2
  • Juliane Hannemann
    • 3
  • Jelle Wesseling
    • 3
  • Marc J. van de Vijver
    • 3
  • Emiel J. Th. Rutgers
    • 1
  • Marie-Jeanne T. F. D. Vrancken Peeters
    • 1
  • Harm van Tinteren
    • 4
  • Laura J. van‘t Veer
    • 2
    • 3
  • Sjoerd Rodenhuis
    • 5
  1. 1.Department of Surgical OncologyThe Netherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  2. 2.Agendia BVAmsterdamThe Netherlands
  3. 3.Department of PathologyThe Netherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  4. 4.Department of BiometricsThe Netherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  5. 5.Department of Medical OncologyThe Netherlands Cancer Institute – Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands